Randomized, Placebo-controlled Study Comparing Efficacy of Fluticasone/Salmeterol Combination to Advair in Asthmatics

首次发布于 2015 年 7 月 14 日

ADVAIR DISKUS® (Fluticasone Propionate/Salmeterol) Inhaler Versus SEREVENT DISKUS® (Salmeterol) Inhlaer On Inflammatory Cells And Markers In Chronic Obstructive Pulmonary Disease. ADVAIR DISKUS® and SEREVENT DISKUS® Inhalers Are Trademarks of the GSK Group of Companies.

计划入组 180 人 · 首次发布于 2006 年 6 月 30 日

ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.

计划入组 740 人 · 首次发布于 2005 年 9 月 5 日

GSK-1614235/GSK-2330672

GSK-3844766A

GSK-0932

Gsk Consumer Healthcare Sarl

Denmark

GlaxoSmithKline

United Kingdom

GLAXOSMITHKLINE TRADING SERVICES LIMITED

Spain

3P Innovation Launches Next-Generation DPI Filling Technology, Promising Faster Production of Inhalable Therapeutics

Cipla Secures FDA Approval for First U.S.-Manufactured Generic Advair Diskus Across All Three Strengths

GSK Licenses Hansoh Pharma's B7-H3 ADC, HS-20093, for $185 Million Upfront